Cargando…

Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature

BACKGROUND: A growing number of studies have demonstrated that immune-related long noncoding ribonucleic acids (irlncRNAs) are potential prognostic factors for lung adenocarcinoma. Two-gene combination patterns could improve the sensitivity of prognostic models, providing us a novel signature constr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Xiangjun, Chen, Guoming, Chen, Zhuangzhong, Li, Jing, Chen, Wenmin, Lin, Jietao, Lin, Lizhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371455/ https://www.ncbi.nlm.nih.gov/pubmed/34421308 http://dx.doi.org/10.2147/IJGM.S325240

Ejemplares similares

Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma
por: Zhuang, Jinman, et al.
Publicado: (2022)

A Data Mining-Based Analysis of Core Herbs on Different Patterns (Zheng) of Non-Small Cell Lung Cancer
por: Qi, Xiangjun, et al.
Publicado: (2021)

A novel prognostic signature of immune-related lncRNA pairs in lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2021)

Immune-Related lncRNA Pairs as Prognostic Signature and Immune-Landscape Predictor in Lung Adenocarcinoma
por: Yin, Zhengrong, et al.
Publicado: (2022)

Identification and Validation of a Novel Immune-Related Four-lncRNA Signature for Lung Adenocarcinoma
por: Wang, Jixin, et al.
Publicado: (2021)

Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma
por: Jin, Donghui, et al.
Publicado: (2020)

Comprehensive analysis of clinical prognosis and CLIC1 immune invasion in lung adenocarcinoma
por: Chen, Zhiqiang, et al.
Publicado: (2022)

Construction of an immune-related lncRNA pairs model to predict prognosis and immune landscape of lung adenocarcinoma patients
por: Liu, Junhui, et al.
Publicado: (2021)

Construction of disulfidptosis-related lncRNA signature for predicting the prognosis and immune escape in colon adenocarcinoma
por: Chen, Pan, et al.
Publicado: (2023)

Immune‐related eight‐lncRNA signature for improving prognosis prediction of lung adenocarcinoma
por: Chen, Yan, et al.
Publicado: (2021)

Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review
por: Qi, Xiangjun, et al.
Publicado: (2022)

Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma
por: Sun, Jian-Xuan, et al.
Publicado: (2021)

An immune-related lncRNA signature for the prognosis of pancreatic adenocarcinoma
por: Qi, Bing, et al.
Publicado: (2021)

Identification and Application of a Novel Immune-Related lncRNA Signature on the Prognosis and Immunotherapy for Lung Adenocarcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Pyroptosis-Related LncRNA Signatures Correlate With Lung Adenocarcinoma Prognosis
por: Huang, Hua, et al.
Publicado: (2022)

Identification of an Autophagy-Related lncRNA Prognostic Signature and Related Tumor Immunity Research in Lung Adenocarcinoma
por: Chen, Hang, et al.
Publicado: (2021)

Identification and Validation of Immune-Related LncRNA Prognostic Signature for Lung Adenocarcinoma
por: Wu, Guomin, et al.
Publicado: (2021)

Zhengyuan capsules for the treatment of chemotherapy-induced cancer-related fatigue in stage IIIB–IV unresectable NSCLC: study protocol for a randomized, multi-center, double-blind, placebo-controlled clinical trial
por: Lin, Jietao, et al.
Publicado: (2022)

A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma
por: Lu, Yinliang, et al.
Publicado: (2022)

An Immunity-Associated lncRNA Signature for Predicting Prognosis in Gastric Adenocarcinoma
por: Zhao, Xiaowen, et al.
Publicado: (2022)

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study
por: Qi, Xiangjun, et al.
Publicado: (2022)

Immune-Related lncRNA Pairs Clinical Prognosis Model Construction for Hepatocellular Carcinoma
por: Zhu, Yinghui, et al.
Publicado: (2022)

Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma
por: Li, Yue, et al.
Publicado: (2021)

Identification of Immune-Related lncRNA Pairs and Construction and Validation of a New Prognostic Signature of Colon Cancer
por: Xu, Minxian, et al.
Publicado: (2022)

Construction and validation of an angiogenesis-related lncRNA prognostic model in lung adenocarcinoma
por: Gong, Quan, et al.
Publicado: (2023)

Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study
por: Chen, Wenmin, et al.
Publicado: (2023)

Construction of a novel signature based on immune-related lncRNA to identify high and low risk pancreatic adenocarcinoma patients
por: Li, Na, et al.
Publicado: (2023)

Integrated analysis of hypoxia-associated lncRNA signature to predict prognosis and immune microenvironment of lung adenocarcinoma patients
por: Shao, Jun, et al.
Publicado: (2021)

Integrated Dissection of lncRNA-miRNA-mRNA Pairs and Potential Regulatory Role of lncRNA PCAT19 in Lung Adenocarcinoma
por: Tang, Xiaomei, et al.
Publicado: (2022)

Comprehensive Analysis of an Individualized Immune-Related lncRNA Pair Signature in Gastric Cancer
por: Nie, Chuang, et al.
Publicado: (2022)

Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort)
por: Lin, Jietao, et al.
Publicado: (2023)

A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma
por: Ye, Chen, et al.
Publicado: (2022)

Characterization of a ferroptosis and iron-metabolism related lncRNA signature in lung adenocarcinoma
por: Yao, Jie, et al.
Publicado: (2021)

Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD
por: Chen, Hang, et al.
Publicado: (2021)

Construction and Validation of a Necroptosis-Related lncRNA Signature in Prognosis and Immune Microenvironment for Glioma
por: Jiang, Fan, et al.
Publicado: (2022)

A novel glycosyltransferase-related lncRNA signature correlates with lung adenocarcinoma prognosis
por: Bian, Chengyu, et al.
Publicado: (2022)

An Aggrephagy-Related LncRNA Signature for the Prognosis of Pancreatic Adenocarcinoma
por: Huang, Xueyuan, et al.
Publicado: (2023)

Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma
por: Wang, Fangwei, et al.
Publicado: (2022)

Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis
por: Li, Hanrong, et al.
Publicado: (2023)

Construction of an immune‐related LncRNA signature with prognostic significance for bladder cancer
por: Luo, Wen‐Jie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6tkbvm1kb02vj9qjc4atd44ora